Risk prediction score for clinical outcome in atrial fibrillation and stable coronary artery disease
Objective Antithrombotic therapy is essential for patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) because of the high risk of thrombosis, whereas a combination of antiplatelets and anticoagulants is associated with a high risk of bleeding. We sought to develop and val...
Main Authors: | Satoshi Yasuda, Hisao Ogawa, Masato Nakamura, Kenichi Tsujita, Atsushi Hirayama, Masaharu Akao, Junya Ako, Katsumi Miyauchi, Nobuhisa Hagiwara, Koichi Kaikita, Tetsuya Matoba, Kazuo Kimura, Kunihiko Matsui, Masanobu Ishii, Eiichiro Nishihara, Shinichiro Nakamura |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-02-01
|
Series: | Open Heart |
Online Access: | https://openheart.bmj.com/content/10/1/e002292.full |
Similar Items
-
Rivaroxaban Monotherapy in Patients With Atrial Fibrillation and Coronary Stenting at Multiple Vessels or the Left Main Trunk: The AFIRE Trial Subanalysis
by: Mitsuru Ishii, et al.
Published: (2022-11-01) -
Antithrombotic Therapy for Atrial Fibrillation and Coronary Artery Disease in Patients With Prior Atherothrombotic Disease: A Post Hoc Analysis of the AFIRE Trial
by: Yasushi Matsuzawa, et al.
Published: (2021-11-01) -
Thrombocytopenia as a Bleeding Risk Factor in Atrial Fibrillation and Coronary Artery Disease: Insights From the AFIRE Study
by: Raisuke Iijima, et al.
Published: (2023-10-01) -
Determinants of Myocardial Lactate Production During Acetylcholine Provocation Test in Patients With Coronary Spasm
by: Koichi Kaikita, et al.
Published: (2015-12-01) -
When Is the Optimal Timing of Surgical Intervention for Severe Functional Tricuspid Regurgitation?
by: Nobuhiro Nakanishi, et al.
Published: (2017-01-01)